Last reviewed · How we verify

NCT05554965

Endoscopic Hemostatic and Sedative Treatment of Esophageal and Gastric Variceal Bleeding

Status unknown Phase 4 Last updated 10 November 2022
What this trial tests

Phase 4 trial testing Propofol in Endoscopic Hemostasis in 60 participants. Status unknown.

Timeline
10 February 2022
Primary endpoint
30 October 2022
30 December 2022

Quick facts

Lead sponsorRenmin Hospital of Wuhan University
PhasePhase 4
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment60
Start date10 February 2022
Primary completion30 October 2022
Estimated completion30 December 2022
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Renmin Hospital of Wuhan University

Who can join

Adults 18 to 80, any sex, with Endoscopic Hemostasis or Sedation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Remazolam besylate was used for sedation during endoscopic hemostasis in patients with esophageal and gastric varices rupture and bleeding in liver cirrhosis. The onset time, recovery time and incidence of adverse reactions were observed.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Propofol

Trials testing the same drug.

Other Renmin Hospital of Wuhan University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05554965.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing